

Haematologica
HAEMATOL/2017/180059
Version 3

Desmopressin in moderate hemophilia A patients: a treatment worth
considering

Janneke I. Loomans, Marieke J.H.A. Kruij, Manuel Carcao, Shannon Jackson, Alice S. van Velzen, Marjolein Peters, Elena Santagostino, Helen Platokouki, Erik Beckers, Jan Voorberg, Johanna G. van der Bom, and Karin Fijnvandraat

Disclosures: M Carcao has received research funding from Baxalta (now a part of Shire), Bayer HealthCare, Biogen, Novo Nordisk and Pfizer; additionally, he has received honoraria for advisory board participation and for speaking from Baxalta (now a part of Shire), Bayer HealthCare, Biogen, Biotest, CSL Behring, Novo Nordisk, Octapharma, and Pfizer. E.S. has participated in advisory boards for Bayer, Pfizer, Novo Nordisk, and CSL Behring, has received payment for consultancy meetings with Grifols and Kedrion, has received grants from Pfizer and Novo Nordisk, has received payment for lectures from Biotest and Octapharma, and has received travel expenses paid by Baxter. J.G.v.d.B. has received payment for consultancy meetings with Bayer and Wyeth, has received grants from Bayer Schering Pharma, Baxter, CSL Behring, Novo Nordisk, and Wyeth, and has received payment for lectures from Bayer. K.F. is a member of the European Hemophilia Treatment and Standardization Board sponsored by Baxter, has received unrestricted research grants from CSL Behring, Pfizer, and Bayer, and has given lectures at educational symposiums organized by Pfizer and Bayer. The remaining authors declare no competing financial interests.

Contributions: Contribution: J.L. interpreted and analyzed the data and wrote the manuscript; all co-authors reviewed and approved the final version of the manuscript; and K.F. designed the study.